Physician profile
William T Long
NPI 1497708168
$2,556.21
in general payments reported to CMS, 2019-2025
27 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $31.30 · 2023: $695 · 2024: $867 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Education: $81.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.26 |
| Education | $81.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.06 | 2019-2025 | |
| Janssen Biotech, INC. | $568.14 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $173.59 | 2023-2025 | Sotyktu |
| Amgen INC. | $161.45 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $118.98 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $93.15 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $83.17 | 2019-2025 | Absorica Ld, Winlevi |
| Cipher Pharmaceuticals US LLC | $79.80 | 2025 | Natroba, Spinosad |
| Novartis Pharmaceuticals Corporation | $67.17 | 2019-2024 | |
| Almirall LLC | $62.10 | 2023-2024 | Seysara |
| Celgene Corporation | $60.75 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.79 | 2019-2023 | Dupixent |
| Leo Pharma INC. | $45.37 | 2019 | |
| Galderma Laboratories, L.P. | $45.09 | 2024-2025 | Nemluvio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.91 | 2023-2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $43.50 | 2019-2024 | Clear & Brilliant, Fraxel |
| Esperion Therapeutics, INC. | $36.10 | 2023-2024 | Nexletol |
| Mayne Pharma Commercial LLC | $35.71 | 2023 | |
| Botanix Sb INC | $24.26 | 2025 | Sofdra |
| Genzyme Corporation | $23.64 | 2024 | |
| Arcutis Biotherapeutics, INC. | $20.69 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $19.79 | 2025 | Xtrac |
| Allergan, INC. | $18.77 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.12 | 2019 | |
| Mission Pharmacal Company | $16.87 | 2019 | |
| Genentech USA, INC. | $15.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.